Hidrokortizon Altamedics

Hidrokortizon Altamedics is an oral tablet containing hydrocortisone, a glucocorticoid corticosteroid. It is marketed in the European Union and supplied by prescription. The product provides systemic glucocorticoid activity for conditions requiring hormone replacement or anti‑inflammatory therapy. Its formulation is designed for oral administration, but specific dosage strengths are not disclosed in the available data. The medication belongs to the corticosteroid class and is intended for use under medical supervision.

Hidrokortizon Altamedics is prescribed for systemic conditions that need glucocorticoid hormone replacement or potent anti‑inflammatory effects, typically when oral therapy is appropriate.

- Adrenal insufficiency such as Addison’s disease, providing physiological cortisol replacement. - Acute adrenal crisis, delivering rapid systemic glucocorticoid support. - Severe inflammatory or allergic disorders (e.g., dermatitis, vasculitis) requiring oral corticosteroid therapy. - Certain autoimmune diseases (e.g., systemic lupus erythematosus) where immunosuppression is indicated. - Severe asthma or chronic obstructive pulmonary disease exacerbations that are managed with oral steroids. - Transition or tapering from high‑dose intravenous steroids to oral hydrocortisone for continued control.

Adverse reactions to oral hydrocortisone can vary from mild and transient to potentially serious, depending on dose and duration of therapy.

Common: - Increased appetite and gradual weight gain, often accompanied by fluid retention and mild peripheral edema. - Elevated blood glucose levels that may be noticeable in patients with pre‑existing diabetes or predisposition. - Insomnia, anxiety, or irritability, reflecting central nervous system effects. - Gastrointestinal discomfort such as nausea or mild abdominal pain.

Serious: - Suppression of the hypothalamic‑pituitary‑adrenal axis, which can precipitate adrenal crisis if the drug is abruptly stopped. - Increased susceptibility to severe infections, including bacterial, viral, or fungal pathogens, due to immunosuppressive action. - Development of hypertension, osteoporosis, or peptic ulcer disease with long‑term high‑dose therapy.

When prescribing Hidrokortizon Altamedics, clinicians consider several precautionary measures to minimize risks and ensure safe use. - Assess baseline cortisol production and adrenal function before initiating therapy. - Use the lowest effective dose for the shortest duration necessary. - Monitor blood pressure, blood glucose, and electrolyte levels regularly during treatment. - Evaluate for a history of peptic ulcer disease, osteoporosis, or severe infections. - Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal insufficiency. - Consider potential effects on pregnancy and lactation; use only if benefits outweigh risks.

Hydrocortisone can interact with other medicines, altering its efficacy or increasing adverse effects.

Avoid: - Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone levels. - Combining with other systemic glucocorticoids, which can amplify immunosuppression and metabolic side effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration. - Anticoagulants such as warfarin, as glucocorticoids can affect clotting factor synthesis. - Diabetic medications, because hydrocortisone may raise blood glucose and require dose adjustments. - Vaccines, particularly live attenuated vaccines, may have reduced efficacy or cause infection.